Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalNo recent work listed

Xin Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0818-994X; OpenAlex author ID A5100333176. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 2 papers

Papers 4

  1. Upregulated GPRC5A disrupting the Hippo pathway promotes the proliferation and migration of pancreatic cancer cells via the cAMP-CREB axis. First author DOI 10.1007/s12672-023-00626-1↗
  2. ABHD17C, a metabolic and immune-related gene signature, predicts prognosis and anti-PD1 therapy response in pancreatic cancer. Co-author DOI 10.1007/s12672-023-00690-7↗
  3. FAT10 promotes chemotherapeutic resistance in pancreatic cancer by inducing epithelial-mesenchymal transition via stabilization of FOXM1 expression. Co-author DOI 10.1038/s41419-022-04960-0↗
  4. Deubiquitinase USP18 promotes the progression of pancreatic cancer via enhancing the Notch1-c-Myc axis. Last author DOI 10.18632/aging.103760↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rongfa Yuan · 2 shared papers, 2020–2022 · strength 0.24
  2. Weidan Fang · 1 shared paper, 2023 · strength 0.22
  3. Mei Ma · 1 shared paper, 2023 · strength 0.22
  4. Jianping Xiong · 1 shared paper, 2023 · strength 0.22
  5. Tongguo Si · 1 shared paper, 2023 · strength 0.20
  6. Weihao Zhang · 1 shared paper, 2023 · strength 0.20
  7. Yongjie Xie · 1 shared paper, 2023 · strength 0.20
  8. Leifeng Chen · 1 shared paper, 2022 · strength 0.13
  9. Chen Huan Luo · 1 shared paper, 2022 · strength 0.13
  10. Jinfeng Zhu · 1 shared paper, 2022 · strength 0.13
  11. Jiefeng Zhao · 1 shared paper, 2022 · strength 0.13
  12. Fanqin Bu · 1 shared paper, 2022 · strength 0.13
  13. Long Feng · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.